EPAD

The European Prevention of Alzheimer's Dementia Consortium (EPAD)  is a unique and ground-breaking European initiative to streamline the testing and development of preventative treatments for Alzheimer’s disease.

Jule Duffus, first participant enrolled in dementia study, with Professor Craig Ritchie

The largest ever public-private partnership in Alzheimer’s disease research, EPAD combines knowledge and expertise from 39 organisations across multiple sectors. Together, we are developing a platform on which new compounds can be tested in a streamlined and efficient way, delivering more effective, targeted interventions that can slow or stop dementia.

 

Currently Recruiting: No

Visit the EPAD website

 

Data Access

 

This article was published on